Abstract
New macrolides, such as clarithromycin and azithromycin, are active agents to Mycobacterium avium complex (MAC). Both clarithromycin and azithromycin are well-known for the ability to improve the prognosis of AIDS patients with disseminated MAC infection. However, the administration of monotherapy with a macrolide is usually associated with the emergence of drug resistance after a few months of use. Therefore, the recommended treatment for MAC infection involved the use of at least two antibiotics, which includes a macrolide in combination with rifabutin, moxifloxacin and / or ethambutol. When used as prophylactic therapy in AIDS patients, azithromycin is more convenient (1200 mg, once a week) than clarithromycin (500 mg, twice a day). Ketolides are a semi-synthetic derivative of erythromycin A, which differs from erythromycin A by substitution of a 3- keto group for L-cladinose. Telithromycin has a carbamate group linked to an imidazolium and pyridium nucleus at C11- C12. In mice model, both telithromycin and ABT-733 were active in vivo against MAC.
Keywords: macrolides, clarithromycin, azithromycin, roxithromycin
Current Pharmaceutical Design
Title: Effects of Macrolides and Ketolides on Mycobacterial Infections
Volume: 10 Issue: 26
Author(s): Luiz E. Bermudez and Yoshitaka Yamazaki
Affiliation:
Keywords: macrolides, clarithromycin, azithromycin, roxithromycin
Abstract: New macrolides, such as clarithromycin and azithromycin, are active agents to Mycobacterium avium complex (MAC). Both clarithromycin and azithromycin are well-known for the ability to improve the prognosis of AIDS patients with disseminated MAC infection. However, the administration of monotherapy with a macrolide is usually associated with the emergence of drug resistance after a few months of use. Therefore, the recommended treatment for MAC infection involved the use of at least two antibiotics, which includes a macrolide in combination with rifabutin, moxifloxacin and / or ethambutol. When used as prophylactic therapy in AIDS patients, azithromycin is more convenient (1200 mg, once a week) than clarithromycin (500 mg, twice a day). Ketolides are a semi-synthetic derivative of erythromycin A, which differs from erythromycin A by substitution of a 3- keto group for L-cladinose. Telithromycin has a carbamate group linked to an imidazolium and pyridium nucleus at C11- C12. In mice model, both telithromycin and ABT-733 were active in vivo against MAC.
Export Options
About this article
Cite this article as:
Bermudez E. Luiz and Yamazaki Yoshitaka, Effects of Macrolides and Ketolides on Mycobacterial Infections, Current Pharmaceutical Design 2004; 10 (26) . https://dx.doi.org/10.2174/1381612043383241
DOI https://dx.doi.org/10.2174/1381612043383241 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dihydrofolate Reductase as a Model for Enzyme Catalysis
Current Biotechnology Emerging Electrical Biosensors for Detecting Pathogens and Antimicrobial Susceptibility Tests
Current Organic Chemistry Anti-cytokines and Cytokines in the Treatment of Rheumatoid Arthritis
Current Pharmaceutical Design Application of Metabolomics in Drug Discovery, Development and Theranostics
Current Metabolomics Advances in Nanoparticles as Anticancer Drug Delivery Vector: Need of this Century
Current Pharmaceutical Design Nanodelivery Systems for Mucosal Vaccines
Recent Patents on Nanomedicine In Vivo Induced Antigen Technology (IVIAT) and Change Mediated Antigen Technology (CMAT)
Infectious Disorders - Drug Targets Effect on Serum Uric Acid Levels of Drugs Prescribed for Indications other than Treating Hyperuricaemia
Current Pharmaceutical Design Cancer Nanotechnology: Emerging Role of Gold Nanoconjugates
Anti-Cancer Agents in Medicinal Chemistry Reverse Pharmacognosy: Another Way to Harness the Generosity of Nature
Current Pharmaceutical Design Immune Restoration Disease: A Consequence of Dysregulated Immune Responses After HAART
Current HIV Research Investigation of the Antimycobacterial Activity of 8-hydroxyquinolones
Medicinal Chemistry Staphylococcus aureus: Current State of Prevalence, Impact, and Vaccine Development
Current Pharmaceutical Design Quinoxaline Derivatives: Novel and Selective Butyrylcholinesterase Inhibitors
Medicinal Chemistry Regulation of Protective and Pathogenic Th17 Responses
Current Immunology Reviews (Discontinued) Contemporary Overview on Clinical Trials and Future Prospects of Hepato-protective Herbal Medicines
Reviews on Recent Clinical Trials Anti-Infective Strategies of the Future: Is there Room for Species-Specific Antibacterial Agents?
Current Pharmaceutical Design Synthesis, Characterization, Antimicrobial, Anti-tubercular, Antioxidant Activities and Docking Simulations of Derivatives of 2-(pyridin-3-yl)-1Hbenzo[ d]imidazole and 1,3,4-Oxadiazole Analogy
Letters in Drug Design & Discovery Inhibition of Drug Efflux in Mycobacteria with Phenothiazines and Other Putative Efflux Inhibitors
Recent Patents on Anti-Infective Drug Discovery Potential of Natural Products of Herbal Origin as Monoamine Oxidase Inhibitors
Current Pharmaceutical Design